Selexipag
Top View
- Clinical Use of Extended-Release Oral Treprostinil in the Treatment of Pulmonary Arterial Hypertension
- Preferred Drug List Drug Class Review Announcement
- Magellan Rx Report
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- Interactions with Experimental COVID-19 Therapies
- Increased Role of E Prostanoid Receptor-3 in Prostacyclin
- Beraprost Modified Release in Addition to Treprostinil for Pulmonary Arterial Hypertension
- Preferred Drug List (PDL)
- Reimbursement Criteria for Frequently Requested Drugs
- Selexipag (Uptravi ) Issued by PHA’S Scientific Leadership Council
- Mississippi Division of Medicaid Universal Preferred Drug
- USP Category USP Class Example Part D Eligible Drugs* Salt/Ester
- USP Medicare Model Guidelines V7.0 (With Example Part D Drugs)
- Blue Cross and Blue Shield April 2021 Multi-Tier Basic Drug List
- Therapeutic Drug Class
- Diverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary 5 Hypertension
- EFFECTIVE 01/01/2017 Version 2017.1J
- Quantity Limits — Select